WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001087889) CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/087889    International Application No.:    PCT/US2001/016326
Publication Date: 22.11.2001 International Filing Date: 18.05.2001
Chapter 2 Demand Filed:    14.12.2001    
IPC:
C07D 487/16 (2006.01), C07D 498/16 (2006.01)
Applicants: NEUROCRINE BIOSCIENCES, INC. [US/US]; 10555 Science Center Drive, San Diego, CA 92121 (US) (For All Designated States Except US).
HADDACH, Mustapha [MA/US]; (US) (For US Only)
Inventors: HADDACH, Mustapha; (US)
Agent: HERMANNS, Karl, R.; Seed Intellectual Property Law Group PLLC, Suite 6300, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).
GOWSHALL, Jon V.,; FORRESTER & BOEHMERT, Pettenkoferstr.20-22, D-80336 Munchen (DE)
Priority Data:
60/205,649 18.05.2000 US
Title (EN) CRF RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO
(FR) ANTAGONISTES DU RECEPTEUR DE LA CRF ET METHODES ASSOCIEES
Abstract: front page image
(EN)CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke. The CRF receptor antagonists of this invention have the following structure (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein m, R, R1, R2, A, and X are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.
(FR)L'invention porte sur des antagonistes du récepteur de la CRF (corticolibérine) utilisables dans le traitement de différents troubles dont ceux se manifestant par une hypersécrétion de CRF liée à une attaque chez les animaux à sang chaud. Lesdits antagonistes du récepteur de la CRF présentent la structure suivante (I)(qui comprend des stéréoisomères et leurs sels pharmacocompatibles) dans laquelle n m, R, R1, R2, A, et X sont définis dans la description. L'invention porte également sur des compositions contenant un antagoniste du récepteur de la CRF combiné à un vecteur pharmacocompatible, et sur leurs méthodes d'utilisation.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)